Dr. Hu Jiong currently holds the positions of Deputy Director of the Hematology Department and Director of the Bone Marrow Transplantation (BMT) Unit at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Dr. Hu is a full member of the American Society of Hematology, serving on the Academic Committee of Myeloid Neoplasm. He is also a distinguished member of the Global Committee of the European Society for Blood and Marrow Transplantation (EBMT). In addition to his impressive affiliations, Dr. Hu serves as the vice president of the Shanghai Hematology Physicians Branch of the Chinese Medical Association, and the deputy director of the Shanghai Society for Transplant Immunology.

Pr. Hu has contributed his expertise to the Hematology Department for adults at Saint-Louis Hospital in Paris, France, as well as the prestigious Bone Marrow Transplantation Center at Queen Mary Hospital, Hong Kong, China. In 2023, he successfully completed his postdoctoral research at the esteemed National Heart, Lung, and Blood Institute (NIH-NHLBI) in the United States.

Pr. Hu has dedicated his career to advancing both basic and clinical research in the field of hematopoietic stem cell transplantation. His primary focus has been on optimizing clinical treatment systems and exploring drug resistance mechanisms and targeted reversal therapies in leukemia. His remarkable contributions include leading four projects funded by the prestigious National Natural Science Foundation, receiving a research grant from the Shanghai Outstanding Young Physician Program, and having published over 100 SCI papers.

In recognition of his outstanding achievements, He has been awarded the second prize of the National Natural Science Award in 2016 (as the fourth contributor), the grand prize of the Shanghai Natural Science Award in 2015 (as the fourth contributor), and the 2022 EBMT Young Leader Award.

Dr. SHAO Yilin is currently an oncologist at Jiahui International Cancer Center. Dr. Shao graduated from Shanghai Medical College Fudan University (8-year program in clinical medicine) with a Ph.D. in oncology. She was granted the outstanding graduate of Fudan University. Before joining Jiahui Health, Dr. Shao completed her standardized training of residents at Fudan University Shanghai Cancer Center and then worked at the Cancer Centre of Shanghai Tenth People’s Hospital. Dr. Shao has several years of clinical experience in medical oncology, especially in diagnosis and treatment of breast cancer and other common cancer. She has been involved in various clinical research projects and has published several SCI papers.

Dr. Lisa FENG is currently a medical oncologist of Jiahui International Cancer Center, graduated from the First Affiliated Hospital of Zhengzhou University with a Master of Medicine degree (hematology) in 2013. Before joining Jiahui Health, she has worked in two hematonosis hospitals. During 6 years of clinical practice, she has accumulated experience in advanced hematology oncology treatments such as allogeneic hematopoietic stem cell transplantation and CAR-T. Dr. Feng specializes in the treatment of common benign and malignant hematological diseases such as leukemia, lymphoma, myelodysplastic syndrome and aplastic anemia, including allogeneic hematopoietic stem cell transplantation techniques and CAR-T techniques.

Dr. Dong Yan is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a bachelor’s degree in Clinical Medicine from Peking University Health Science Center in 2002 and received her Ph.D. from the Graduate School of Medicine at the University of Tokyo in 2008. Before joining Jiahui Health, Dr. Dong worked at Tongji Hospital in Shanghai.

Dr. Dong has dedicated her career to clinical and research work in hematology. She is highly proficient in diagnosing and treating a wide range of common blood disorders, including various types of anemia, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), and thrombocytopenia. She has also accumulated clinical experience in advanced blood cancer therapies such as autologous stem cell transplantation, allogeneic hematopoietic stem cell transplantation, and CAR-T.

Dr. Dong has published several papers in both domestic and international core journals and is currently a committee member of the Hematology Branch of Shanghai Medical Association（SMA）.

Dr. MAO Aiqin is currently a medical oncologist at Jiahui International Cancer Center. She graduated from Xin Xiang Medical College with a bachelor's degree in 1997 and was engaged in teaching and clinical research of internal medicine at the affiliated Hospital of Henan Polytechnic University. In 2010, she received her master's degree in Clinical Oncology from Guang Xi Medical University. After graduation, she has been working in clinical practice and has rich knowledge in internal medicine and oncology.

Before joining Jiahui, Dr. Mao served as the associate chief physician at the Third Ring Hospital of Cancer Hospital of Chinese Academy of Medical Sciences and the Department of Oncology of Boao Evergrande International Hospital. She has long been engaged in front-line clinical work in the department of oncology and has accumulated rich clinical experience. Dr. Mao specializes in standardized chemotherapy and palliative treatment of many cancer types, especially for precision personalized treatment for lung and breast cancer. She is also a highly responsible individual who is patient-centered.

In terms of clinical research, Dr. Mao has participated in many clinical trials/projects and has published many clinical oncology-related papers.

Dr. WANG Hongzhe is currently an oncologist at Jiahui International Cancer Center. Dr. Wang graduated from Guangxi Medical University in 2008 with a Master's degree in Internal Medicine. After graduation, Dr. Wang has long been engaged in front-line clinical work and has participated in many clinical teaching and research exchanges with the Dana-Farber Cancer Institute (DFCI) in China. Dr. Wang insists on the principle of individualized treatment in the diagnosis and comprehensive medical treatment of common malignant tumors in medical oncology. He specializes in diagnosis and comprehensive treatment of malignant lymphoma, lung cancer, breast cancer and other malignant tumors.

Dr. Vicky LEE, MD, PhD is Director of Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, and she has over 30 years of experience in the cancer research and clinical care field. She is an internationally well-known expert in medical oncology, hematology and cancer risk assessment. Dr. LEE has worked 3 years for Peking University First Hospital, and then went to Kyoto University School of Medicine (Japan) and New York University School of Medicine (United States) for further study in breast cancer research and cancer immunology research. Before joining Jiahui Health, Dr. LEE worked in medical oncology for over 20 years in the United States. Since 1995 in US, she has been board certified in American Board of Internal Medicine (ABIM), American Board of Hematology and American Board of Medical Oncology. She received Certificate of Intensive Course in Cancer Genetic Risk Assessment at City of Hope in 2018. She also has Oregon State Medical License and Washington State Medical License.

Dr. LEE is currently a board member of the Washington State Society of Medical Oncology (WSMOS), and is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the Oregon Society of Medical Oncology (OSMO).

With solid knowledge and professional training in USA, clinical experience in treating cancer patients, Dr. LEE is familiar with advanced international techniques in cancer prevention, diagnosis and treatment. She is skilled in the treatment of rare and complex cancers, and is adept at communicating with patients and their families. Dr. Vicky LEE always encourages patients to participate in decision making of cancer treatment plan with doctors, as this will enhance patients’ understanding of the disease. Hence, they will corporate well with the treatment plan and achieve better outcome. Dr. LEE cares about patients’ quality of life and good at manage patients’ cancer pain through standardized and individualized treatment plans.

Dr. LEE specializes in hematology and oncology treatment including but not limited to:

· Treatment of solid tumor, special interest in breast cancer, melanoma, colon cancer, and lung cancer.
· Management of blood tumors, especially in myeloma and lymphoma.
· Diagnosis and treatment of benign hematological diseases involving antithrombotic therapy and management of myeloproliferative disorders, MDS.
· Cancer Genetics consultation and cancer risk assessment.
· Palliative Care and Management of cancer pain.

Dr. Andrew X. ZHU, MD, PhD serves as a multi-site practice physician at Jiahui International Cancer Center. Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma(HCC) and cholangiocarcinoma, Dr. Zhu has served as a principle investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.

Dr. Andrew X. Zhu is a founding board member of the International Liver Cancer Association(ILCA), Fellow of American College of Physicians (ACP), and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and former Professor of Medicine at Harvard Medical School.

Dr. Andrew X. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009. The hepatobiliary cancer MDT included experts from Surgical Oncology, Transplant Surgery, Interventional Radiology, Radiation Oncology, Hepatology and Pathology. In addition, Dr. Andrew X. Zhu led a series of pivotal clinical studies in advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma(BTC) during his tenure as director of Liver Cancer Research at the Mass General Cancer Center. As the lead global principal investigator, he led the pivotal studies which led to the regulatory approval of pembrolizumab and ramucirumab in advanced HCC. As a co-principal investigator, he is lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations, which has met the primary endpoint. Under the leadership of Dr. Andrew X. Zhu, he and his team established the hepatocellular cancer treatment center in New England, USA, which has become one of the most active clinical research centers for liver cancer in the United States.